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Abstract 
Detection of HFE Haemochromatosis (HH) is challenging in the absence of clinical features. HH 
subjects have elevated erythrocyte parameters compared to those without HH, but it remains 
unclear how this could be applied in clinical practice. Thus, we determined the sensitivity, 
specificity and clinical utility of erythrocyte parameters in 144 HH subjects with (n=122) or 
without (n=22) clinical and/or biochemical expression of iron overload, 1844 general population 
controls, and 700 chronic disease subjects. For both expressing and non-expressing HH subjects, 
the mean pre- and post-phlebotomy values of mean cell volume (MCV) and mean cell 
haemoglobin (MCH) were always significantly higher when compared to all other groups and 
demonstrated excellent diagnostic utility for detection of HH in men and women (AUROC 0.83-
0.9; maximal sensitivity and specificity 82% and 78%) using cut-off values for MCV >91 fL or 
MCH >31 pg, respectively. Between 34 and 62% of all HH subjects would be detected, and less 
than 4% of all non-HH subjects would undergo unnecessary testing, if those with MCV or MCH 
values greater than 94 fL or 32.2 pg, respectively, were evaluated. 
Keywords 
HFE Haemochromatosis; screening; diagnosis; mean cell volume; mean cell haemoglobin 
Abbreviations 
AUROC curve – area under receiver operator characteristic curve 
HH – HFE Haemochromatosis 
MCH – mean cell haemoglobin 
MCV – mean cell volume 
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Introduction 
HFE hemochromatosis (HH) is a genetic disorder most commonly attributed in populations 
of northern European descent to the presence of a homozygous C282Y mutation in the HFE-gene 
product1-5. Most HH subjects are now ascertained with relatively few or no symptoms on the basis 
of family screening or incidental documentation of elevated serum transferrin saturation and ferritin 
levels2, 3, 5. Biochemical or genetic screening is generally reserved for subjects with a family history 
of the disorder or clinical presentation with symptoms characteristic of the disorder2, 3, 5. Whilst there 
has been much debate regarding general population screening, it is not currently recommended2, 3, 6, 
7.  
There is much evidence supporting the clinical benefits of early detection, including 
improvement of symptoms and signs of disease2, 3, 5, 8,9. Treatment of HH individuals with elevated 
ferritin levels prior to the onset of cirrhosis is associated not only with long-term survival identical 
to that of age- and gender-matched controls in the general population8 but also to marked 
improvement in symptoms and quality of life9. Many individuals with HH derive satisfaction from 
knowing that the treatment of their disorder results in the provision of blood products for transfusion 
purposes10. 
Previous studies have reported that HH subjects exhibited significant differences in 
peripheral blood erythrocyte parameters compared with controls11-12. The mean values of 
haemoglobin (Hb), haematocrit, mean cell volume (MCV), mean cell haemoglobin (MCH) and 
mean cell haemoglobin concentration (MCHC) were all elevated compared with controls. After 
therapeutic phlebotomy, the MCV, MCH and MCHC values of HH subjects all decreased but 
remained elevated compared with controls. However, in these studies up to 16% of subjects had 
cirrhosis, raising the possibility that clinical presentations were more advanced than is currently 
observed11-12. The aim of our study was to evaluate the sensitivity and specificity of erythrocyte 
parameters as screening tests for detection of HH compared with general population controls and 
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randomly selected subjects with a range of chronic diseases including liver disease, rheumatological 
disease, diabetes mellitus and chronic pulmonary disease. 
Methods  
Subjects 
The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was 
approved by the Human Research Ethics Committees of The University of Western Australia and 
The Queensland Institute of Medical Research. Consecutive HH subjects (n=122) aged between 20 
and 70 years who were referred for initial diagnosis and treatment from primary care to metropolitan 
community-based Hepatology services between 2005 and 2015 were included in the study. Only 
subjects with C282Y homozygosity were included. Our exclusion criteria were; pregnant or lactating 
women, venesection in the previous 12 months, malignancy, and acute inflammatory conditions.  
Laboratory investigations available for HH subjects at initial assessment included haematology, 
serum iron biochemistry, HH genotyping, liver biochemistry, chronic viral hepatitis serology, 
screens for autoimmune liver disease, Wilson disease, alpha-1 antitrypsin genotype, and whether 
subjects were thought to have cirrhosis.  All HH subjects with serum ferritin levels elevated above 
300 µg/L underwent therapeutic phlebotomy at weekly intervals until the ferritin level was between 
50 and 100 µg/L. Haematology parameters and serum iron biochemistry were monitored throughout 
therapy. A second group of 22 men and women with HH who did not have elevated ferritin levels 
or clinical symptoms were included for comparison purposes. General population control subjects 
comprised 900 men and 944 women aged between 20 and 70 years who did not have a C282Y 
homozygous nor C282Y/H63D compound heterozygous mutation and who were enrolled in the 
Busselton Population Study, Western Australia4.  Baseline haematology parameters were available 
for all subjects. All blood tests were performed in accredited laboratories. For comparison with other 
chronic inflammatory diseases, we randomly selected a total of 700 subjects, with equal numbers of 
men and women,  attending outpatient clinics with chronic liver disease (including cirrhosis, chronic 
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hepatitis C, and chronic hepatitis B), rheumatological disease (rheumatoid arthritis and non-
rheumatoid arthritis), diabetes mellitus, or chronic pulmonary disease.  
Statistical Analysis 
All data are presented as the mean ± SEM unless otherwise specified. Analysis of variance 
was used to analyse differences between groups and area under the receiver operator characteristic 
(AUROC) curve analysis was performed for evaluation of sensitivity and specificity of erythrocyte 
parameters in the diagnosis of HH. All statistical tests were conducted using GraphPad Prism 7 
(GraphPad Software, San Diego, CA). Statistical significance was assigned for p<0.05. 
Results 
Patient Characteristics 
Clinical characteristics of HH subjects at initial diagnosis are shown in Table 1. 70 men and 
52 women with clinical and/or biochemical expression of HH were enrolled in this study. 
Approximately 44% of men and 48% of women in this cohort experienced symptoms related to HH, 
with the most common symptom being lethargy and joint pain. 14 of 70 men (20%) and 6 of 52 
women (12%) had a history of excessive alcohol consumption (greater than 3 standard drinks per 
day for men or 2 standard drinks per day for women). More men than women had abnormal liver 
biochemistry (p=0.004). 4 of 70 men whilst none of the women had clinically or histologically 
confirmed cirrhosis.  
Subjects with HH were significantly younger compared to their gender-matched controls and 
those with cirrhosis, diabetes and pulmonary disease (Table 2). Men with HH were significantly 
younger compared to gender-matched controls with rheumatoid and non-rheumatoid arthritis but 
women were significantly younger compared to gender-matched controls with rheumatoid arthritis 
only. As expected, clinically detected HH subjects had significantly higher serum ferritin levels 
compared to the control and chronic disease subjects (p<0.001). Phlebotomy treatment resulted in 
significant reductions in ferritin levels in both men and women with HH compared with pre-
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treatment values (p<0.0001 for both men and women, Table 2). The maximal combinations of 
sensitivity and specificity for ferritin using cut-off values determined in our study for the detection 
of HH in pre-treatment men (ferritin cut-off 380 µg/L) was 92% and 89%, respectively whilst in 
women (ferritin cut-off 227 µg/L) both these values were 92%. 
For pre-treatment, post-treatment and non-expressing HH subjects, the mean pre-treatment 
values of MCV and MCH in men and women were significantly higher when compared to the 
general population control and chronic disease other groups (Table 2, p<0.001). The same was 
observed for MCV and MCH following treatment of iron-loaded HH subjects. The MCV and MCH 
also demonstrated excellent diagnostic utility for detection of HH, especially for pre-treatment HH, 
as shown in the AUROC analysis (Tables 3 and 4, Figures 1 and 2). For pre-treatment men and 
women, the AUROC ranged between 0.83 and 0.9, providing maximal sensitivity and specificity of 
82% and 78% using cut-off values for MCV >91 fL or MCH >31 pg, respectively. 
             The 90% sensitivity and 90% specificity cut-off thresholds for MCV and MCH are 
reported in Table 5. Less than 10% of subjects with HH would be left undiagnosed if subjects with 
values below the 90% sensitivity threshold values for MCV or MCH were not further assessed. Up 
to 9% of non-HH subjects in the general population also have MCV or MCH values below these 
thresholds. 
  Less than 10% of subjects who underwent further work-up for HH for values above the 
90% specificity thresholds for MCV or MCH would not have HH. Overall, 1-4% of non-HH 
subjects in the general population control group have MCV or MCH values above the 90% 
specificity threshold, whilst 34% to  62% of pre-treatment HH subjects fit in this category. This 
group is substantially enriched for finding HH (likelihood ratio up to 30 times more likely than 
non-HH subjects).  
Discussion 
		
7	
HH in populations of northern European descent is generally suspected in the clinic 
following elucidation of a family history, clinical features compatible with a diagnosis or detection 
of elevated serum iron studies.  Definitive diagnosis requires documentation of elevated body iron 
stores and confirmatory testing for causative HFE gene mutations5,13. Screening for HH outside 
these settings or in asymptomatic general populations of appropriate genetic background are not 
currently recommended and is	 not	 cost-effective	 using	 combinations	 of	 HFE	 genotyping,	transferrin	saturation,	and	serum	ferritin2, 3, 6, 7.      
 Ascertaining those at risk of HH would be made easier if other routine blood tests could 
provide indications for the likely presence of C282Y homozygosity.  In this study we evaluated the 
potential utility of standard erythrocyte parameters as tests for the detection of C282Y 
homozygosity.  We have found that MCV and MCH were the most appropriate erythrocyte 
parameters and these values were significantly higher in both men and women with C282Y 
homozygosity, independent of their treatment status. 
  The observations of the current study combined with the earlier study of Barton et al.11-12 
suggests that MCV and MCH could add to the range of parameters that inform the clinician on a 
likelihood of HH. Erythrocyte parameters are commonly ordered for routine clinical assessment and 
when within the reference range they are often paid limited attention. For example, Australia has a 
population of 24 million14 and there are almost 12 million full blood examinations performed per 
annum which assess Hb, MCH, MCV and other erythrocyte parameters15.  There are over twice as 
many full blood examinations performed each year compared with the combined totals of serum 
iron studies, ferritin or HFE genotyping15.  Targeted further assessment of subjects with MCV >94 
fL would identify 34% of untreated men and 62% of untreated women with HH in our general 
population. This would result in unnecessary further evaluation of less than 4% of the general 
population who do not have HH. Utilisation of a MCH threshold of >32.2 pg would identify 34% of 
untreated men and 47% of untreated women with HH, incurring unnecessary testing in 1% of the 
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general population who do not have HH. The yield of identification of unsuspected HH if evaluation 
is limited to those above the 90% specificity cut-offs in Table 5 is up to 30 times that of general 
population screening.  Further cost modelling analysis of the utility of such an approach is warranted. 
We extended our analysis to include populations with chronic disease such as chronic 
hepatitis B, chronic hepatitis C, cirrhosis, rheumatologic diseases, diabetes mellitus and chronic 
pulmonary diseases. Overall, the utility of MCH can be extended to these chronic disease groups, 
with less discriminatory value for MCV especially in those with chronic hepatitis C, cirrhosis or 
rheumatoid arthritis.  The 90% sensitivity thresholds remained constant within the general and 
chronic diseases populations. Thus, subjects with values below these values have an extremely low 
likelihood of having HH and can be excluded from further evaluation at the cost of missing less than 
10% of unsuspected HH in our community. The 90% specificity cut-off values were higher in the 
combined chronic diseases group compared with the general population.  Less than 8% of the 
combined chronic diseases group who do not have HH have values greater than the 90% specificity 
cut-offs for MCV or MCH. 
 The mechanisms underlying the erythrocyte manifestations of C282Y homozygosity are 
unclear.  The persistence of elevated MCV and MCH values in C282Y homozygous subjects 
following adequate phlebotomy therapy indicates that the abnormality is not purely a reflection of 
iron status.  Indeed, when we compared the erythrocyte parameters of a small group of HH subjects 
who had not yet developed elevated ferritin levels or clinical features with our study cohorts, we 
observed the same findings of elevated MCV and MCH. Thus, the erythrocyte anomalies occur 
before elevation of total body iron stores develops. Interestingly, MCV and MCH values increase 
significantly and incrementally from wild-type HFE to C282Y simple heterozygotes and then further 
again in C282Y/H63D compound heterozygotes16. The levels of MCV and MCH which we observed 
in our C282Y homozygotes are markedly greater in comparison with our previously published 
observations in C282Y/H63D compound heterozygotes16. Taken together, these observations 
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suggest that the MCV and MCH changes may be due to the direct effects of C282Y and H63D 
mutations in HFE per se. It is known that the HFE protein is not expressed in erythrocytes17, and it 
has previously been proposed that the elevated MCV and MCH in subjects with HH may be due to 
increased iron supply to erythroblasts18. Although other studies have reported that European and 
United States subjects with HH exhibit higher Hb levels compared with controls18-20, we have not 
observed this in our Australian subjects. It is possible that this difference may be due to geographic 
variation in other genetic or environmental factors that influence iron status21,22. 
Our observations confirm and extend those of previous investigators11-12, indicating these 
findings are valid and relevant to HH.  As we have not studied subjects with non-C282Y HH, we 
are unable to confirm whether similar erythrocyte manifestations may be present in these disorders. 
Furthermore, as we have not evaluated infants, children or adolescents, the proposed approach using 
erythrocyte parameters can only be recommended for adults. Another limitation is the relatively 
small number of subjects with chronic disease that were analysed and larger sample sizes would 
likely add strength to our observations of the utility of MCV and MCH screening in subjects with 
chronic inflammatory conditions. Ideally, the most appropriate means of validating the utility of the 
proposed screening strategy outlined in Figure 3 would be to conduct a prospective study.  
Conclusion 
We conclude that MCV and MCH are able to guide further assessment for the presence of 
otherwise unsuspected HH, with added advantages over ferritin including utility following 
successful therapy and in screening chronic disease subjects. Further cost analyses of such 
approaches to screening are warranted to guide further consideration of clinical implementation. 
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Figure Legends 
FIGURE 1. AUROC curves for MCV and MCH in pre- and post-treatment HH men. Comparisons 
were made with the control group and the combined chronic diseases group. The AUROC for each 
analysis is shown within each graph. 
 
FIGURE 2. AUROC curves for MCV and MCH in pre- and post-treatment HH women. 
Comparisons were made with the control group and the combined chronic diseases group. The 
AUROC for each analysis is shown within each graph. 
 
FIGURE 3.  Suggested approach to investigation for presence of HH in subjects based on provision 
of MCV or MCH results from full blood picture analysis. 
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TABLE 1. Characteristics	of	men	and	women	with	HFE	hemochromatosis	at	diagnosis. 
 
 Male Female P value* 
n 70 52  
Symptoms 31 25 0.72 
     Lethargy 30 17 0.27 
     Joint pain 12 12 0.49 
Alcohol excess 
history1 
14 6 0.32 
Cirrhosis 4 0 0.13 
Abnormal liver 
biochemistry2 
22 5 0.004 
* Fisher’s exact test 
1greater than 3 standard drinks per day for males or 2 standard drinks per day for females. 
2Refers to levels above the cut-off for upper end of the reported reference range for liver 
biochemical tests. 
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TABLE 2. General and erythrocyte characteristics of clinically or biochemically diagnosed study subjects. 
Male N Age (yrs) Hb (g/L) MCV (fL) MCH (pg) MCHC (g/L) Ferritin (µg/L) 
HH 70       
 Pre-treat  43±2 153±2 94±0.5 32±0.2 345±1 1225±138 
 Post-treat  43±2 149±2 93±0.5 32±0.2 343±1 63±4*** 
 Non-expressing 9 36±6 152±3 95±1 33±0.3 343±2 152±3*** 
Busselton 900 50±0.5** 150±0.3 89±0.1*** 30±0.05*** 343±0.2 217±7*** 
Noncirrhotic        
 Hepatitis C 50 53±1 150±3 92±0.7 31±0.3** 339±1 283±29*** 
 Hepatitis B 50 45±2 152±2 89±0.8** 30±0.3*** 337±2* 528±154*** 
Cirrhosis 50 52±1* 146±4 92±0.9 31±0.5*** 338±1 406±52*** 
Arthritis        
 Rheumatoid  50 62±2*** 145±2* 92±0.8 31±0.3*** 334±2*** 237±35*** 
 Non-rheumatoid 50 56±2** 150±2 91±0.6*** 30±0.3*** 338±2* 212±34*** 
Diabetes 50 59±2*** 139±3*** 87±0.7*** 29±0.3*** 334±1** 264±43*** 
Chronic Lung 50 67±2*** 142±3*** 90±0.9*** 30±0.3*** 330±2*** 300±83*** 
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Female N Age (yrs) Hb (g/L) MCV (fL) MCH (pg) MCHC (g/L) Ferritin (µg/L) 
HH 52       
 Pre-treat  45±2 138±1 96±0.7 32±0.2 339±1 510±39 
 Post-treat  46±2 139±2 94±0.8 32±0.3 342±2 68±6*** 
 Non-expressing 13 48±3 143±3 97±1 33±0.3 341±2 117±22*** 
Busselton 944 54±0.5** 134±0.3 88±0.2*** 31±0.06*** 341±0.2 100±4*** 
Noncirrhotic        
 Hepatitis C 50 51±1 137±2 91±0.7*** 31±0.3*** 337±1 164±34*** 
 Hepatitis B 50 42±2 132±2 88±0.8*** 29±0.4*** 331±1 119±37*** 
Cirrhosis 50 58±1*** 123±3*** 93±0.1 31±0.4*** 333±1 281±61*** 
Arthritis        
 Rheumatoid 50 58±2* 130±2* 90±0.8*** 30±0.3*** 329±2 167±31*** 
 Non-rheumatoid 50 52±2 138±21 90±0.7*** 30±0.3*** 330±2 107±12*** 
Diabetes 50 59±2*** 128±3** 87±0.8*** 29±0.3*** 330±2 151±20*** 
Chronic Lung 50 68±2*** 132±2 89±0.6*** 29±0.2*** 328±2 128±25*** 
All values ±SEM. All statistical comparisons are with the HH pre-treatment group. The Busselton and Chronic Diseases Groups are comprised of 
subjects who do not possess C282Y homozygosity or C282Y/C63D compound heterozygosity. *p<0.05; **p<0.01; ***p<0.001
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TABLE 3. Sensitivity, specificity, and AUROC curve analysis for MCV and MCH.  
 
MCV > 91fL Sensitivity 
Pre 
 
Post 
Specificity 
Pre 
 
Post 
ROC AUC 
Pre 
 
Post 
Control Population 77 69 69 69 0.83 0.74 
Chronic Disease Groups Combined 77 68 56 56 0.71 0.64 
 
MCH > 31pg Sensitivity 
Pre 
 
Post 
Specificity 
Pre 
 
Post 
ROC AUC 
Pre 
 
Post 
Control Population 77 65 75 75 0.83 0.75 
Chronic Disease Groups Combined 77 65 69 69 0.78 0.72 
Results are presented for male HH pre- and post-treatment subjects compared with the control population and the combined chronic disease 
groups. Cut-off values were selected to give the highest combination of sensitivity and specificity in the general population. 
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TABLE 4. Sensitivity, specificity, and AUROC analysis for MCV and MCH.  
 
MCV > 91fL Sensitivity 
Pre 
 
Post 
Specificity 
Pre 
 
Post 
ROC AUC 
Pre 
 
Post 
Control Population 82 77 78 78 0.90 0.82 
Chronic Disease Groups Combined 82 75 66 66 0.81 0.73 
 
MCH > 31pg Sensitivity 
Pre 
 
Post 
Specificity 
Pre 
 
Post 
ROC AUC 
Pre 
 
Post 
Control Population 72 79 71 72 0.84 0.82 
Chronic Disease Groups Combined 72 79 74 74 0.84 0.81 
Results are presented for female HH pre- and post-treatment subjects compared with the control population and the combined chronic disease 
groups. Cut-off values were selected to give the highest combination of sensitivity and specificity in general population. 
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TABLE 5. Sensitivity	and	specificity	cut-off	thresholds	for	MCV	and	MCH	in	control	and	chronic	disease	populations.  
 
MCV (fl) 90% Sensitivity 90% Specificity 
Control Population 90.0 94.0 
Chronic Disease Groups Combined 90.0 97.5 
 
MCH (pg) 90% Sensitivity 90% Specificity 
Control Population 31.0 32.2 
Chronic Disease Groups Combined 31.0 33.2 
Less than 10 percent of subjects with HH would be left undiagnosed if subjects with values below the 90 percent sensitivity threshold were not 
further assessed. Less than 10 percent of subjects who underwent further work-up for HH for values above the 90% specificity threshold would 
not have HH. 
 
 
 
 
  
 
